Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of CKD-330 vs Candesartan+Amlodipine in Healthy Males
NCT02548286Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of candesartan + amlodipine in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration of Candesartan, Area Under the Plasma Concentration-time curve of Candesartan and 2 more. Started Aug 2015; status: completed.
02
Drugs
candesartan + amlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02548286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548286.